Skip Navigation

Cardiovascular Research 2005 68(2):249-258; doi:10.1016/j.cardiores.2005.06.016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shinohara, M.
Right arrow Articles by Yokoyama, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shinohara, M.
Right arrow Articles by Yokoyama, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Xenogenic smooth muscle cell immunization reduces neointimal formation in balloon-injured rabbit carotid arteries

Masakazu Shinohara, Seinosuke Kawashima*, Tomoya Yamashita, Tomofumi Takaya, Ryuji Toh, Tatsuro Ishida, Tomomi Ueyama, Nobutaka Inoue, Ken-ichi Hirata and Mitsuhiro Yokoyama

Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

* Corresponding author. Tel.: +81 78 382 5846; fax: +81 78 382 5859. Email address: kawashim{at}med.kobe-u.ac.jp

Objective: Intimal hyperplasia plays an important role in a variety of types of vascular remodeling, particularly luminal narrowing after vascular injury. The vascular smooth muscle cells (VSMCs) in the neointimal area are a synthetic phenotype and have different epitopes from VSMCs in the normal media. The synthetic VSMCs in the neointima contain various possible antigens that can be targeted by the immune system. In this study, we tried to develop a new immunotherapy, which targets the synthetic VSMCs, for prevention of neointimal formation after angioplasty.

Method and results: Rabbits were repeatedly immunized with fixed xenogenic rat cultured VSMCs suspended in adjuvant as immunogens or injected with adjuvant and phosphate-buffered saline (PBS) or rat hepatocytes as controls every 2 weeks for 3 times. One week after the last immunization/injection, balloon injury of the left common carotid artery was performed. Four weeks after the injury, rabbits were euthanized and the neointimal lesion formation was assessed. The mean neointimal area of the PBS-injected, non-immunized group and the rat hepatocyte-immunized, control group was not statistically different (0.339 ± 0.036 and 0.350 ± 0.041 mm2, P = NS). However, immunization with rat VSMCs significantly reduced the intimal lesion area (0.219 ± 0.0286 mm2; P<0.05 vs. PBS-injected, non-immunized group and rat hepatocyte-immunized group.) PCNA-immunopositive proliferating VSMCs in the neointima were suppressed by the rat VSMC immunization (1.34 ± 0.49% vs. 5.78 ± 0.47%; P<0.05 vs. PBS-injected, non-immunized group). Rat VSMC immunization induced antibodies which had strong cross-reactivity against rabbit synthetic VSMCs. In experiments in vitro, proliferation and migration of rabbit VSMCs that were stimulated by serum, angiotensin (AT) II, platelet-derived growth factor (PDGF)-BB, fibroblast growth factor (FGF), and the phorbol ester PMA were significantly suppressed by treatment with immunoglobulin extracted from the VSMC-immunized rabbit plasma, implying that the immunoglobulin had some global effects on VSMCs. The rat VSMC-immunized rabbit immunoglobulin bound the rabbit AT1a receptor protein, which was expressed in COS7 cells by transfection of rabbit AT1a receptor pcDNA3. This binding to AT1a receptor may be one of mechanisms of the effects of VSMC-immunized immunoglobulin.

Conclusion: Xenogenic, synthetic rat VSMC immunization in rabbits induced auto-antibodies against synthetic rabbit VSMCs in a cross-reaction. The induced auto-antibodies against synthetic VSMCs may provide a possibility of new immunotherapy for vascular remodeling that forms neointimal lesions.

KEYWORDS Neointimal formation; Vascular remodeling; Vascular smooth muscle; Antibody; Immunotherpy


Time for primary review 20 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
T. Yamashita, S. Kawashima, T. Hirase, M. Shinohara, T. Takaya, N. Sasaki, M. Takeda, H. Tawa, N. Inoue, K.-i. Hirata, et al.
Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice
Am J Physiol Cell Physiol, September 1, 2007; 293(3): C865 - C873.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Thaunat, G. Caligiuri, A. Nicoletti, and J.-B. Michel
Complexity of antigenic determinants and humoral responses in vascular injury
Cardiovasc Res, November 1, 2005; 68(2): 183 - 185.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.